» Articles » PMID: 36299239

Salmonella Pathogenicity Island 1 Knockdown Confers Protection Against Myocardial Fibrosis and Inflammation in Uremic Cardiomyopathy Via Down-regulation of S100 Calcium Binding Protein A8/A9 Transcription

Overview
Journal Ren Fail
Publisher Informa Healthcare
Date 2022 Oct 27
PMID 36299239
Authors
Affiliations
Soon will be listed here.
Abstract

Background/aim: Uremic cardiomyopathy (UCM) is a characteristic cardiac pathology that is commonly found in patients with chronic kidney disease. This study dissected the mechanism of SPI1 in myocardial fibrosis and inflammation induced by UCM through S100A8/A9.

Methods: An UCM rat model was established, followed by qRT-PCR and western blot analyses of SPI1 and S100A8/A9 expression in myocardial tissues. After alterations of SPI1 and S100A8/A9 expression in UCM rats, the blood specimens were harvested from the cardiac apex of rats. The levels of creatine phosphokinase-MB (CK-MB), blood creatinine, blood urea nitrogen (BUN), and inflammatory cytokines (interleukin [IL]-6, IL-1β, and tumor necrosis factor-α [TNF-α]) were examined in the collected blood. Collagen fibrosis was assessed by Masson staining. The expression of fibrosis markers [transforming growth factor (TGF)-β1, α-smooth muscle actin (SMA), Collagen 4a1, and Fibronectin], IL-6, IL-1β, and TNF-α was measured in myocardial tissues. Chromatin immunoprecipitation and dual-luciferase reporter gene assays were conducted to test the binding relationship between SPI1 and S100A8/A9.

Results: S100A8/A9 and SPI1 were highly expressed in the myocardial tissues of UCM rats. Mechanistically, SPI1 bound to the promoter of S100A8/A9 to facilitate S100A8/A9 transcription. S100A8/A9 or SPI1 knockdown reduced myocardial fibrosis and inflammation and the levels of CK-MB, blood creatinine, and BUN, as well as the expression of TGF-β1, α-SMA, Collagen 4a1, Fibronectin, IL-6, TNF-α, and IL-1β in UCM rats.

Conclusion: SPI1 knockdown diminished S100A8/A9 transcription, thus suppressing myocardial fibrosis and inflammation caused by UCM.

Citing Articles

Unraveling the Mechanisms of S100A8/A9 in Myocardial Injury and Dysfunction.

Xu Y, Wang Y, Ning K, Bao Y Curr Issues Mol Biol. 2024; 46(9):9707-9720.

PMID: 39329929 PMC: 11429546. DOI: 10.3390/cimb46090577.


Advances in the study of S100A9 in cardiovascular diseases.

Chen F, He Z, Wang C, Si J, Chen Z, Guo Y Cell Prolif. 2024; 57(8):e13636.

PMID: 38504474 PMC: 11294427. DOI: 10.1111/cpr.13636.

References
1.
Li G, Hao W, Hu W . Transcription factor PU.1 and immune cell differentiation (Review). Int J Mol Med. 2020; 46(6):1943-1950. DOI: 10.3892/ijmm.2020.4763. View

2.
Wang X, Shapiro J . Evolving concepts in the pathogenesis of uraemic cardiomyopathy. Nat Rev Nephrol. 2019; 15(3):159-175. DOI: 10.1038/s41581-018-0101-8. View

3.
Swindell W, Johnston A, Xing X, Little A, Robichaud P, Voorhees J . Robust shifts in S100a9 expression with aging: a novel mechanism for chronic inflammation. Sci Rep. 2013; 3:1215. PMC: 3564041. DOI: 10.1038/srep01215. View

4.
Muller I, Vogl T, Kuhl U, Krannich A, Banks A, Trippel T . Serum alarmin S100A8/S100A9 levels and its potential role as biomarker in myocarditis. ESC Heart Fail. 2020; 7(4):1442-1451. PMC: 7373886. DOI: 10.1002/ehf2.12760. View

5.
Hu J, Zhang J, Li L, Wang S, Yang H, Fan X . PU.1 inhibition attenuates atrial fibrosis and atrial fibrillation vulnerability induced by angiotensin-II by reducing TGF-β1/Smads pathway activation. J Cell Mol Med. 2021; 25(14):6746-6759. PMC: 8278085. DOI: 10.1111/jcmm.16678. View